FDA Analysis Suggests Potential Pituitary Tumor Signal For Risperdal
This article was originally published in The Pink Sheet Daily
Review of adverse event reporting system of pituitary tumors and antipsychotics shows the “vast majority” of tumors were with risperidone. Further data is needed before the signal would be posted on FDA’s drug safety watch list, the agency says. J&J will analyze the study and other data to determine if further studies are needed.
You may also be interested in...
FDA has posted drug-specific safety information for more than 200 products on a Center for Drug Research & Evaluation Research web page
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.